These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 8884115

  • 1. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [Abstract] [Full Text] [Related]

  • 2. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G, Ruebe M, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [Abstract] [Full Text] [Related]

  • 3. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ, First MR, Hurtubise PE, Marmer DJ, Martin DM, Mansour ME, Melvin DB.
    J Heart Transplant; 1989 Aug; 8(5):371-80. PubMed ID: 2529358
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M, Latter DA, Loertscher R.
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [Abstract] [Full Text] [Related]

  • 6. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P.
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
    Meiser BM, Uberfuhr P, Fuchs A, Schulze C, Nollert G, Mair H, Martin S, Pfeiffer M, Reichenspurner H, Kreuzer E, Reichart B.
    J Heart Lung Transplant; 1997 Aug; 16(8):795-800. PubMed ID: 9286771
    [Abstract] [Full Text] [Related]

  • 9. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Aug; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 10. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M, Lake KD, Pritzker MR, Jorgensen CR, Arom KV, Love KR, Emery RW.
    J Heart Lung Transplant; 1991 Aug; 10(6):901-11. PubMed ID: 1661608
    [Abstract] [Full Text] [Related]

  • 11. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
    Oh HK, Provenzano R, Tayeb J, Satmary N, Jones B.
    Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329
    [Abstract] [Full Text] [Related]

  • 12. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR, O'Sullivan EJ, Hubbell EA, Zucker MJ, Pifarre R, McManus BM, Winters GL, Scanlon PJ, Robinson JA.
    J Heart Transplant; 1989 Aug; 8(4):288-95. PubMed ID: 2504895
    [Abstract] [Full Text] [Related]

  • 13. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
    Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, Astellas Corticosteroid Withdrawal Study Group.
    Ann Surg; 2008 Oct; 248(4):564-77. PubMed ID: 18936569
    [Abstract] [Full Text] [Related]

  • 14. OKT3 treatment of cardiac allograft rejection.
    Haverty TP, Sanders M, Sheahan M.
    J Heart Lung Transplant; 1993 Oct; 12(4):591-8. PubMed ID: 8369321
    [Abstract] [Full Text] [Related]

  • 15. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP, Frazier OH, Lammermeier D, Radovancevic B, Duncan JM.
    J Heart Transplant; 1989 Oct; 8(4):281-7. PubMed ID: 2504894
    [Abstract] [Full Text] [Related]

  • 16. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L, Walker J, Klassen D, Oldach D, Schweitzer E, Bartlett ST, Weir MR.
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [Abstract] [Full Text] [Related]

  • 17. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
    Guttmann RD, Flemming C.
    Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
    [Abstract] [Full Text] [Related]

  • 18. The duration of administration of monoclonal antibody OKT3 for induction immunosuppression after heart transplantation.
    Aleksic I, Freimark D, Blanche C, Czer LS, Dalichau H, Valenza M, Takkenberg JJ, Trento A.
    Thorac Cardiovasc Surg; 1997 Aug; 45(4):190-5. PubMed ID: 9323821
    [Abstract] [Full Text] [Related]

  • 19. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
    Toyoda M, Galfayan K, Wachs K, Czer L, Jordan SC.
    Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
    [Abstract] [Full Text] [Related]

  • 20. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
    Shield CF, Hughes JD.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.